Merck & Co is to axe development of two COVID-19 vaccine candidates, focusing on development of two therapies instead following disappointing results in early trials.

Moderna and Merck said their experimental vaccine in ... when demand plummeted for its Covid vaccine, for now its only ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna (NASDAQ:MRNA) is planning to launch a messenger-RNA-based vaccine for skin cancer as early as next year, Japanese ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Merck & Co has joined with the non-profit scientific research organisation, the International AIDS Vaccine Initiative (IAVI), to develop a potential vaccine against the SARS-CoV-2 coronavirus that ...

US pharma giant Merck has scrapped two coronavirus vaccine candidates after they failed to produce an adequate immune response in early trials, the company announced Monday. The vaccines were ...

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the expansion of the newly ...

Merck has officially joined the sprint for a coronavirus treament or vaccine. While dozens of biopharmaceutical companies have started this research, Merck stands apart as one of a few companies ...

Moderna aims to reduce its research and development budget by about 20 percent over the next three years as the biotech tries to find a path to profitability following disappointing vaccine sales.

These lines blurred during COVID-19, when all sectors collaborated closely to accelerate vaccine development. In addition to the AstraZeneca–Oxford and Moderna-NIH partnerships, Merck agreed to ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...